Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Mirati Announces Clearance of IND Application for MRTX849 Trial

americanpharmaceuticalreviewDecember 03, 2018

Tag: Mirati , MRTX849 , IND , KRAS G12C mutations.

PharmaSources Customer Service